Title : Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer - Miura_2018_Support.Care.Cancer_26_3811 |
Author(s) : Miura T , Mitsunaga S , Ikeda M , Ohno I , Takahashi H , Suzuki H , Irisawa A , Kuwata T , Ochiai A |
Ref : Support Care Cancer , 26 :3811 , 2018 |
Abstract :
PURPOSE: Acyl ghrelin is an orexigenic peptide. Active ghrelin ratio, the ratio of acyl ghrelin to total ghrelin, has an important role in physiological functions and gastrointestinal symptoms. However, low active ghrelin ratio-related characteristics, gastrointestinal symptoms, and chemotherapy-induced gastrointestinal toxicity in patients with advanced pancreatic cancer have not been previously evaluated. The goal of this study was to identify low active ghrelin ratio-related factors in treatment-naive advanced pancreatic cancer patients. METHODS: Patients with treatment-naive advanced pancreatic cancer were eligible for inclusion in this study. Active ghrelin ratio and clinical parameters of patients were prospectively recorded. Factors correlated with low active ghrelin ratio and survival were analyzed. RESULTS: In total, 92 patients were analyzed. Low active ghrelin ratio-related factors were advanced age (P < 0.01), severe appetite loss (P < 0.01), and decreased cholinesterase (P < 0.01). The adverse events of grade 2 or higher anorexia tended to increase in patients with low active ghrelin ratio. However, no differences were found in survival and body composition between low and high active ghrelin ratio groups. CONCLUSIONS: Low active ghrelin ratio was related to lack of appetite and low cholinesterase and tended to be related to anorexia grade 2 or higher in patients with treatment-naive advanced pancreatic cancer. |
PubMedSearch : Miura_2018_Support.Care.Cancer_26_3811 |
PubMedID: 29777378 |
Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Suzuki H, Irisawa A, Kuwata T, Ochiai A (2018)
Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer
Support Care Cancer
26 :3811
Miura T, Mitsunaga S, Ikeda M, Ohno I, Takahashi H, Suzuki H, Irisawa A, Kuwata T, Ochiai A (2018)
Support Care Cancer
26 :3811